Global
Merck to present new data on long-term efficacy of GARDASIL®9 and GARDASIL® at EUROGIN 2026
Data highlight long-term effectiveness of HPV vaccines and their role in preventing HPV-related cancers
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that it will present new clinical and real-world data reinforcing the long-term effectiveness of its 9-valent HPV vaccine, GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant), and its 4-valent HPV vaccine, GARDASIL® (Human Papillomavirus 4-valent Vaccine, Recombinant), at the EUROGIN International Multidisciplinary HPV Congress 2026, scheduled to take place in Vienna, Austria, from March 18–21.
The data to be presented include findings from studies assessing long-term vaccine effectiveness in women aged 16 to 26 years. Results show that the 9-valent vaccine remains effective for at least 14 years following three doses, while the quadrivalent vaccine demonstrates effectiveness for up to 18 years after three doses against HPV 16/18-related high-grade cervical disease.
Merck will also present additional data on certain HPV-related oropharyngeal cancers, as well as adult- and juvenile-onset Recurrent Respiratory Papillomatosis (RRP), based on studies conducted in the United States, Denmark, Sweden and the United Kingdom.
“Nearly two decades after the U.S. FDA approval of GARDASIL in June 2006, we are proud to present these data for GARDASIL 9 and GARDASIL that reinforce the long-term effectiveness and importance of HPV vaccination for females ages 9 to 45 years, beginning in adolescence,” said Dr. Paula Annunziato, senior vice president, infectious diseases and vaccines, global clinical development, Merck Research Laboratories. “Additionally, data on certain HPV-related oropharyngeal cancers highlight the importance of HPV vaccination in helping to prevent these cancers, which impact both women and men.”
The data to be presented include findings from studies assessing long-term vaccine effectiveness in women aged 16 to 26 years. Results show that the 9-valent vaccine remains effective for at least 14 years following three doses, while the quadrivalent vaccine demonstrates effectiveness for up to 18 years after three doses against HPV 16/18-related high-grade cervical disease.
Merck will also present additional data on certain HPV-related oropharyngeal cancers, as well as adult- and juvenile-onset Recurrent Respiratory Papillomatosis (RRP), based on studies conducted in the United States, Denmark, Sweden and the United Kingdom.
“Nearly two decades after the U.S. FDA approval of GARDASIL in June 2006, we are proud to present these data for GARDASIL 9 and GARDASIL that reinforce the long-term effectiveness and importance of HPV vaccination for females ages 9 to 45 years, beginning in adolescence,” said Dr. Paula Annunziato, senior vice president, infectious diseases and vaccines, global clinical development, Merck Research Laboratories. “Additionally, data on certain HPV-related oropharyngeal cancers highlight the importance of HPV vaccination in helping to prevent these cancers, which impact both women and men.”
Cancer PreventionEUROGIN 2026GARDASIL 9
